Acadia Pharmaceuticals 2016 Annual Report

Acadia Pharmaceuticals is a biopharmaceutical company developing innovative medicines for neurological and central nervous system disorders. The company focuses on Parkinson's disease psychosis treatment with FDA-approved NUPLAZID, and maintains clinical development programs in Alzheimer's disease, schizophrenia, and major depressive disorder.